GPT-5.6 Terra

Intrinsic YES value is about 67% versus a 71.2% market price. The modest gap does not justify buying, and no sell inventory is available.

Intrinsic YES odds of 42% are only modestly below the 46% YES price. The edge is too small relative to OS-endpoint and disclosure uncertainty, so no trade is attractive.

Intrinsic YES odds of 62% are materially below the 70.4% YES price. The oral-site endpoint and event-rate uncertainty make NO underpriced despite a favorable vaccine mechanism.

Intrinsic YES odds of 43% imply NO is worth about 57%, versus a 48¢ NO price. The 9-point edge supports a moderate buy given endpoint and execution uncertainty.

Intrinsic YES estimate of 61% is only modestly above the 58.0% YES price. Given endpoint/event-rate uncertainty and no meaningful valuation edge, hold.

Intrinsic YES odds of 78% exceed the 72% market price. Buy YES at a moderate size because the pediatric population creates residual efficacy and execution uncertainty.

Intrinsic YES value is about 58% versus a 61% market price. The small negative edge does not justify a buy, and no sell position is feasible.

Intrinsic YES odds of 55% exceed the 42% YES price by 13 points. Buy YES at a moderate size because the active-controlled Phase 3 outcome remains uncertain.

Intrinsic YES odds of 44% are only modestly below the 46% YES price. The small edge does not justify a position given substantial endpoint and noninferiority uncertainty.

Intrinsic YES odds of 48% imply NO is worth about 52%, versus a 40% NO price. Buy NO with moderate sizing because key efficacy and enrollment details are undisclosed.

Intrinsic YES odds of 58% exceed the 45.8% YES price by about 12 points. With no existing exposure and full buying capacity, BUY_YES offers the best value.

Intrinsic YES odds of 39% are only modestly above the 34.5% market price. The edge is too small relative to Phase 3 uncertainty to justify a purchase.

Intrinsic YES odds are only modestly above the 28.1% market price, while endpoint and evidence uncertainty are substantial. The valuation edge is too small to justify adding exposure.

Intrinsic YES value is only modestly above the 0.62 market price, and the stringent durable responder endpoint plus ongoing recruitment leave insufficient edge for a new position.

Intrinsic YES odds of 44% are only modestly below the 47% YES price. The edge is too small relative to sparse efficacy detail and long execution uncertainty.

Intrinsic YES probability of 72% exceeds the 62% market price by about 10 points. Buy YES at a moderate size because the active comparator and long-duration execution add material uncertainty.

Intrinsic YES odds of 43% are only modestly above the 39% YES price. The edge is too small relative to Phase 3 uncertainty to justify a new position.

Intrinsic YES odds of 43% imply NO is worth about 57%, versus a 46% NO price. The 11-point valuation gap supports a moderate BUY_NO position.

Intrinsic YES odds are only modestly above the 50% price. With no disclosed efficacy magnitude or event-rate support in the trial facts, the edge is too uncertain to deploy capital.

Intrinsic YES odds of 62% are essentially aligned with the 61% YES price. The small edge does not justify a large buy given long-duration Phase 3 execution and disclosure risk.

Intrinsic YES odds are about 61% versus a 68% YES price. The modest negative edge is not sufficient to buy NO given endpoint and event-rate uncertainty; no sell capacity is available.

Intrinsic YES odds of 43% are only modestly below the 46% YES price, while phase 3 uncertainty is high. The valuation gap is too small to justify a position.